Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Earnings Results, Beats Estimates By $0.23 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.23, RTT News reports. The company had revenue of $14.97 million for the quarter. During the same period in the previous year, the company earned ($0.37) earnings per share.

Barinthus Biotherapeutics Stock Performance

Shares of BRNS stock traded down $0.01 during mid-day trading on Thursday, reaching $1.47. 6,533 shares of the company were exchanged, compared to its average volume of 23,581. The business's 50 day simple moving average is $1.29 and its 200 day simple moving average is $1.58. The company has a market capitalization of $57.94 million, a P/E ratio of -0.90 and a beta of -0.59. Barinthus Biotherapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $4.39.

Analysts Set New Price Targets

Several analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a report on Thursday, September 26th. Alliance Global Partners dropped their target price on Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating on the stock in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.